Cargando…

Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study

The coronavirus disease 2019 (COVID‐19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential step, from screening to treatment, during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Brugel, Mathias, Carlier, Claire, Essner, Christine, Debreuve‐Theresette, Adeline, Beck, Marie‐Françoise, Merrouche, Yacine, Bouché, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873337/
https://www.ncbi.nlm.nih.gov/pubmed/33111460
http://dx.doi.org/10.1002/onco.13578
_version_ 1783649362997411840
author Brugel, Mathias
Carlier, Claire
Essner, Christine
Debreuve‐Theresette, Adeline
Beck, Marie‐Françoise
Merrouche, Yacine
Bouché, Olivier
author_facet Brugel, Mathias
Carlier, Claire
Essner, Christine
Debreuve‐Theresette, Adeline
Beck, Marie‐Françoise
Merrouche, Yacine
Bouché, Olivier
author_sort Brugel, Mathias
collection PubMed
description The coronavirus disease 2019 (COVID‐19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential step, from screening to treatment, during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopathological analyzes, multidisciplinary tumor board meetings (MTBMs), diagnostic announcement procedures (DAPs), and treatments were calculated in two French areas experiencing different pandemic intensity (Reims and Colmar). COVID‐19 has had a dramatic impact in terms of screening (−86% to −100%), diagnosis (−39%), and surgical treatment (−30%). This global decrease in all essential oncology care pathway steps contrasted with the relative stability of chemotherapy (−9%) and radiotherapy use (−16%). Outbreak occurred earlier and with more intensity in Colmar but had a comparable impact in both areas regarding MTMBs and DAPs. The current ONCOCARE‐COV study is still in progress and with a longer follow‐up to analyze postlockdown situation.
format Online
Article
Text
id pubmed-7873337
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-78733372021-02-17 Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study Brugel, Mathias Carlier, Claire Essner, Christine Debreuve‐Theresette, Adeline Beck, Marie‐Françoise Merrouche, Yacine Bouché, Olivier Oncologist Brief Communications The coronavirus disease 2019 (COVID‐19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential step, from screening to treatment, during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopathological analyzes, multidisciplinary tumor board meetings (MTBMs), diagnostic announcement procedures (DAPs), and treatments were calculated in two French areas experiencing different pandemic intensity (Reims and Colmar). COVID‐19 has had a dramatic impact in terms of screening (−86% to −100%), diagnosis (−39%), and surgical treatment (−30%). This global decrease in all essential oncology care pathway steps contrasted with the relative stability of chemotherapy (−9%) and radiotherapy use (−16%). Outbreak occurred earlier and with more intensity in Colmar but had a comparable impact in both areas regarding MTMBs and DAPs. The current ONCOCARE‐COV study is still in progress and with a longer follow‐up to analyze postlockdown situation. John Wiley & Sons, Inc. 2020-11-11 2021-02 /pmc/articles/PMC7873337/ /pubmed/33111460 http://dx.doi.org/10.1002/onco.13578 Text en © 2020 AlphaMed Press
spellingShingle Brief Communications
Brugel, Mathias
Carlier, Claire
Essner, Christine
Debreuve‐Theresette, Adeline
Beck, Marie‐Françoise
Merrouche, Yacine
Bouché, Olivier
Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study
title Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study
title_full Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study
title_fullStr Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study
title_full_unstemmed Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study
title_short Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study
title_sort dramatic changes in oncology care pathways during the covid‐19 pandemic: the french oncocare‐cov study
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873337/
https://www.ncbi.nlm.nih.gov/pubmed/33111460
http://dx.doi.org/10.1002/onco.13578
work_keys_str_mv AT brugelmathias dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy
AT carlierclaire dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy
AT essnerchristine dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy
AT debreuvetheresetteadeline dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy
AT beckmariefrancoise dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy
AT merroucheyacine dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy
AT boucheolivier dramaticchangesinoncologycarepathwaysduringthecovid19pandemicthefrenchoncocarecovstudy